These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 35039353

  • 1. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
    Zand Irani A, Almuwais A, Gibbons H.
    BMJ Case Rep; 2022 Jan 17; 15(1):. PubMed ID: 35039353
    [Abstract] [Full Text] [Related]

  • 2. Pembrolizumab-induced type 1 diabetes.
    Maia A, Soares DM, Azevedo S, Pereira T, Amaral C.
    J Oncol Pharm Pract; 2024 Sep 17; 30(6):1118-1121. PubMed ID: 38766907
    [Abstract] [Full Text] [Related]

  • 3. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
    Tang Y, Zhao Z, Wang X, Zuo W, Zhang B, Yuan T, Fu Y.
    Immunotherapy; 2021 Apr 17; 13(6):483-489. PubMed ID: 33626915
    [Abstract] [Full Text] [Related]

  • 4. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
    Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH.
    Endocrinol Diabetes Metab Case Rep; 2019 Mar 05; 2019():. PubMed ID: 30836329
    [Abstract] [Full Text] [Related]

  • 5. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S, Zhang Y, Sun Z, Hu J, Fang C.
    Medicine (Baltimore); 2018 Nov 05; 97(45):e12907. PubMed ID: 30407284
    [Abstract] [Full Text] [Related]

  • 6. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Jun 29; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 8. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Jun 29; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 9. Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option.
    Greene A, Penner S, Kunesh J, Altaf A, McGrade W, Niu J.
    J Oncol Pharm Pract; 2024 Sep 29; 30(6):1084-1088. PubMed ID: 38544442
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
    Edahiro R, Ishijima M, Kurebe H, Nishida K, Uenami T, Kanazu M, Akazawa Y, Yano Y, Mori M.
    Thorac Cancer; 2019 May 29; 10(5):1276-1279. PubMed ID: 30964601
    [Abstract] [Full Text] [Related]

  • 13. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S, Bae C, Joy-Ann T, Traverse W.
    J Oncol Pharm Pract; 2020 Jun 29; 26(4):995-999. PubMed ID: 31575354
    [Abstract] [Full Text] [Related]

  • 14. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jun 29; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 15. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
    Daetwyler E, Zippelius A, Danioth S, Donath MY, Gut L.
    Front Immunol; 2023 Sep 01; 14():1248919. PubMed ID: 37965350
    [Abstract] [Full Text] [Related]

  • 18. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
    Aleksova J, Lau PK, Soldatos G, McArthur G.
    BMJ Case Rep; 2016 Nov 23; 2016():. PubMed ID: 27881588
    [Abstract] [Full Text] [Related]

  • 19. Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.
    Okubo M, Hataya Y, Fujimoto K, Iwakura T, Matsuoka N.
    J Diabetes Investig; 2023 Jan 23; 14(1):147-150. PubMed ID: 36251515
    [Abstract] [Full Text] [Related]

  • 20. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z, Sharma R, Hamad L, Riebandt G, Attwood K.
    Diabetes Res Clin Pract; 2023 Aug 23; 202():110776. PubMed ID: 37311494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.